AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A method for ~~preventing and/or~~ treating ~~a neurodegenerative disease~~cerebral infarction, ~~neuropathy or a disease whose treatment requires neural regeneration, which comprises~~comprising parenterally administering between about 100 mg to about 2,000 mg ~~to a mammal an effective amount~~ of (2R)-2-propyloctanoic acid or a salt thereof to a mammal.

2-5. (canceled).

6. (original): The method according to claim 1, wherein the parenteral administration is intravenous administration.

7. (original): The method according to claim 6, wherein the intravenous administration is continuous administration.

8. (original): The method according to claim 7, wherein the continuous administration is infusion bag administration.

9. (original): The method according to claim 1, wherein the dose of parenteral administration per once a day during an administration period of 1 day to 100 days is within a range of about 100 mg to about 2,000 mg.

10. (original): The method according to claim 9, wherein the administration period is from 1 day to 10 days.

11. (original): The method according to claim 10, wherein the administration period is 3 days, 4 days, 5 days, 6 days or 7 days.

12. (original): The method according to claim 11, wherein the administration period is 7 days.

13. (original): The method according to claim 1, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

14. (original): The method according to claim 13, wherein the dose per 1 kg of body weight of a patient is about 2 mg, about 4 mg, about 6 mg, about 8 mg, about 10 mg or about 12 mg.

15. (original): The method according to claim 14, wherein the dose per 1 kg of body weight of a patient is about 4 mg or about 8 mg.

16. (original): The method according to claim 1, which is a method for inhibition of S-100β increase.

17. (withdrawn): A method for inhibition of S-100β increase, which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof.

18. (withdrawn): The method according to claim 17, wherein the amount per dose in the parenteral administration is within a range of about 100 mg to about 2,000 mg.

19. (withdrawn): The method according to claim 17, wherein the parenteral administration is intravenous administration.

20. (withdrawn): The method according to claim 17, wherein the dose of parenteral administration per once a day during an administration period of 1 day to 100 days is within a range of about 100 mg to about 2,000 mg.

21. (withdrawn): The method according to claim 17, wherein the dose per 1 kg of body weight of a patient is within a range of about 2 mg to about 12 mg.

22-23. (canceled).

24. (withdrawn): A method for preventing and/or treating cerebral infarction which comprises parenterally administering to a mammal an effective amount of (2R)-2-propyloctanoic acid or a salt thereof in combination with an effective amount of a tissue plasminogen activator.

25. (withdrawn): The method according to claim 24, wherein the dose of (2R)-2-propyloctanoic acid or a salt thereof per 1 kg of body weight of a patient is about 4 mg or about 8 mg, and the dose of the tissue plasminogen activator per 1 kg of body weight of a patient is about 0.6 mg or about 0.9 mg.

26. (withdrawn): The method according to claim 25, wherein the administration is started within 3 hours after onset of the cerebral infarction.

27. (withdrawn): A parenterally administered composition for preventing and/or treating cerebral infarction which comprises (2R)-2-propyloctanoic acid or a salt thereof in combination with a tissue plasminogen activator.

28. (canceled).

29. (original): The method according to claim 1, wherein (2R)-2-propyloctanoic acid is used.

30. (withdrawn): The composition according to claim 27, wherein (2R)-2-propyloctanoic acid is comprised.

31. (canceled).

32. (withdrawn): A method for treating cerebral infarction, which comprises continuously administering to a mammal intravenously (2R)-2-propyloctanoic acid using an infusion bag at a dose of about 4 mg or about 8 mg per 1 kg of body weight during administration period for 7 days.

33. (withdrawn): The method according to claim 17, wherein (2R)-2-propyloctanoic acid is used.

34. (withdrawn): The method according to claim 24, wherein (2R)-2-propyloctanoic acid is used.

35. (currently amended): ~~The~~ A method ~~according to claim 1, wherein said neurodegenerative disease is~~for treating cerebral infarction, ~~and wherein said parenteral administration of an effective amount of (2R)-2-propyloctanoic acid is the~~ comprising ~~continuous administration of~~ continuously administering (2R)-2-propyloctanoic acid intravenously to a mammal using an infusion bag at a dose of about 4 mg or about 8 mg per 1 kg of body weight during an administration period of 7 days.